April 12, 2021. However, globally, almost 1 billion children suffer ET U.S. FDA lifts clinical hold on IND application for COVAXIN (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submission Implied volatility shows how much movement the market is expecting . Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international) Conference ID: 9757658: Webcast: Available in the "Investors" section of the Ocugen website by clicking here and . malvern, pa., may 03, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Interestingly, Sanofi will be one . MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a . Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at . lives of COVID-19, announced today that it will host a conference call to discuss its fourth quarter and full . Over the course of the week, each of the CWU colleges and programs had a day in the spotlight, starting with the College of the . Ocugen’s cash, cash equivalents, and restricted cash totaled $95.1 million as of December 31, 2021, compared to $24.2 million as of December 31, 2020. . OCU410 is the second drug candidate from Ocugen's Modifier Gene Therapy Platform, which is expected to enter clinical trials in 2022. Ocugen, Inc. (NASDAQ:NASDAQ:OCGN) Q3 2021 Earnings Conference Call November 9, 2021, 08:30 AM ET Company Participants Shankar Musunuri - CEO Sanjay Subramanian - CFO Ken Inchausti - Head of. MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will present at the 2021 Cantor Virtual Global Healthcare Conference . DOW 0.00%. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Cancel. Ocugen Inc is expected to have a median price target of $7 per share during the 12-month period, according to four analysts who cover the company. malvern, pa., feb. 18, 2022 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. In depth view into Ocugen Intrinsic Value: Projected FCF explanation, calculation, historical data and more Feb 3, 2021. Conference Call and Webcast Details. But during the Ocugen earnings conference call, Musunuri and CFO Sanjay . ET to Discuss First Quarter 2021 Financial Results and Provide May 3, 2021, 8:35 PM UTC Share this article MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi's 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C . MALVERN, Pa., March 12, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its 2020 financial results and . 9:00 A.M. (ET) - 3:00 P.M. (ET) - One-On-One Investor Meetings. Press J to jump to the feed. April 28, 2021. malvern, pa., july 30, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from covid-19, today announced that it will host a conference call to discuss its second quarter 2021 MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its third quarter 2021 financial results and . Ocugen Inc 2.44 0.27 (12.44%) Watch. Ocugen is on watch as Bharat Biotech plans to ramp up production of its COVAXIN vaccine. MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its second quarter 2021 financial results and provide a business update at 8 . Central Washington University hosted the annual Symposium for University Research and Creative Expression (SOURCE) conference virtually from May 16-21, starting with a welcome event. malvern, pa., march 12, 2021 (globe newswire) -- ocugen, inc. ("ocugen") (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure. Conference Call and Webcast . Conference Call and Webcast Details Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its first quarter 2021 financial results and provide a business update at 8 . MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference being held on March 9-10, the 33 rd Annual . About Ocugen; Our People; Our Partners; . ET on Friday, May 7, 2021. 2021 Virtual SOURCE Conference. Rooms Shows Rankings Earnings Newsletters Shop. ocugen host conference call friday february 25 830 am et discuss Press Release Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. September 7, 2021 - 5:22 pm. NASDAQ 0.00%. MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . Ocugen's senior management team will host the . Ocugen reported a $0.09 net loss per share for the three months ended March 31, 2022 compared to a $0.04 net loss per share for the three months ended March 31, 2021. Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. ET to discuss the fourth quarter and full year 2021 financial results and provide an update on business. MALVERN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the presentation of a pre-clinical study to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular . Chester County biopharmaceutical company Ocugen has finalized an agreement with Bharat Biotech of India to co-develop Bharat's Covid-19 vaccine for the United States market. Ocugen reported a $0.13 net loss per share for the three months ended June 30, 2021 compared to a $0.19 net loss per share for the three months ended June 30, 2020. Third Quarter 2021 Financial Results. ET on Friday, February 25 . Ocugen reported a $0.09 net loss per share for the three months ended March 31, 2022 compared to a $0.04 net loss per share for the three months ended March 31, 2021. Ocugen reported a $0.04 net loss per share for the three months ended March 31, 2021 compared to a $0.07 net loss per share for the three months ended March 31, 2020. Ocugen Provides Business Update and First Quarter 2021 Financial Results May 7, 2021 PDF Version Conference Call and Webcast Today at 8:30 a.m. The 2021 Premier Volleyball League Open Conference was the tenth conference of the Premier Volleyball League ( 37th conference of the former Shakey's V-League) and its first conference as a professional league. We ended the quarter with cash, cash equivalents and restricted cash totaling $115.8 million as of June 30, 2021 compared to $24.2 million on hand as of December 31, 2020. MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN) , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business . Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business updates. MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and develop a vaccine to fight COVID-19, today announced that it will present at the 2021 CTIC 5 th Healthcare Investment Summit being held on January 9-10, the H.C. Wainwright BioConnect . MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8 . May 17, 2021 By Larry Ramer, InvestorPlace Contributor May 17, 2021, 10:37 am EDT May 17, 2021 After reviewing the . MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . "Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. Dear Stockholder: We are pleased to invite you to attend Ocugen, Inc.'s 2021 Annual Meeting of Stockholders (the . the market grew at a rate of 15.5% from 2015 to culminate in a market of $1.60b in 2021. . Dial-In Number: (844) 873-7330 (U.S.) or (602) 563-8473 (international) Conference ID: 9757658: Webcast: Available in the "Investors" section of the Ocugen website by clicking here and archived . ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) ENDING VIOLENCE AGAINST CHILDREN IN THE CONTEXT OF COVID-19 Under the United Nations Convention on the Rights of the Child (1989), girls and boys have the right to be protected from all forms of violence in all settings. S&P 500 0.00%. H. C. Wainwright has a block of rooms at the Fontainebleau Hotel. The 2 nd Annual Dry AMD Therapeutic Development conference requires registration for attendance. Log In. The conference started on July 17, 2021 and ended on August 13, 2021, at the PCV Socio-Civic and Cultural Center in Bacarra, Ilocos Norte in a bubble. March 12, 2021 - 5:45 pm. Dr. Upadhyay will be speaking on October 20, 2021, at 3:15pm Eastern Time. MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its second quarter 2021 financial results and . General and administrative expenses for the quarter ended. ET to Discuss First Quarter 2021 Financial Results and Provide Business Update https://t.co/sBLgNkrfSL" malvern, pa., nov. 02, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Ocugen (NASDAQ: OCGN) is . malvern, pa., nov. 02, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. The Company has scheduled a conference call and webcast for 8:30 a.m. eastern time on August 6, 2021 to discuss these financial results and business updates. [1] [2] [3] The conference started on July 17, 2021 and ended on August 13, 2021, at the PCV Socio-Civic and Cultural Center in Bacarra . In a virtual address to the "AI and Cyber - An Abundance of Potential" conference on Monday (27 September 2021), Deputy Secretary General Mircea Geoan stressed that NATO is determined to set the standard for the ethical use of emerging and disruptive technologies. Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. 2021 ANNUAL MEETING OF STOCKHOLDERSTo be Held on June 11, 2021. Investors are invited to participate on the call using the following details: for the year ended december 31, 2021, ocugen reported a net loss of approximately $58.4 million, or $0.30 net loss per share, compared to net loss of approximately $34.4 million, or $0.31 net loss. We have completed three quarters of 2021 and our Ocugen family has grown significantly, committed to bringing Covaxine BBV152, our COVID-19 vaccine candidate to the United States and Canada. Conference Call and Webcast . 1-5 November 2021 CONFERENCE OUTCOME STATEMENT . Ocugen to Host Conference Call on Friday, May 7 at 8:30 a.m. malvern, pa., march 08, 2021 (globe newswire) -- ocugen, inc. (nasdaq: ocgn), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Sign Up. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene . November 2, 2021 - 6:08 pm. Ocugen's senior management team . ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update February 18, 2022 PDF Version General and administrative expenses for the quarter ended March 31, 2021 or $4.2 million, compared to $2.3 million for the three-month ended March 31, 2020. Ocugen, Inc. Q4 and Full Year 2021 Financial Results and Recent Business Highlights 01/10/2022 H.C. Wainwright Bioconnect Conference 12/22/2021 CEO Shankar Musunuri on the power of Ocugen 11/09/2021 Ocugen Inc Third Quarter 2021 Financial Results and Recent Business Highlights 09/28/2021 2021 Cantor Virtual Global Healthcare Conference 09/13/2021 no. MALVERN, Pennsylvania, Feb. 18 11, 2022 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure diseases of blindness and the development of a vaccine to save lives. MALVERN, Pa. November 9, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, . By Sarah Smith, Editor, Today's Market Apr 12, 2021, 12:29 pm EST. . The in-person conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach, FL. The increase was primarily driven by. The 2021 Premier Volleyball League Open Conference was the tenth conference of the Premier Volleyball League (37th conference of the former Shakey's V-League) and its first conference as a professional league. Ocugen's cash, cash equivalents, and restricted cash totaled $107.5 million as of September 30, 2021, compared to $24.2 million as of December 31, 2020. July 30, 2021 - 8:45 am. Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results February 25, 2022 PDF Version Conference Call and Webcast Today at 8:30 a.m. MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi's 16th Annual BioPharma Virtual Conference being held on . 2021 Financial Results. About. ET on Tuesday, November 9, 2021.. Ocugen will issue a pre-market earnings announcement on the same day. Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights . We have completed three quarters of 2021 and our Ocugen family has grown significantly, committed to bringing Covaxine BBV152, our COVID-19 vaccine candidate to the United States and Canada. Our research and . The remaining increase is attributed to the continued investment in the development activities for Covaxin and our ocular portfolio. MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness . On August 6, 2021, Ocugen, Inc. ("the Company") issued a press release announcing its financial results for the quarter ended June 30, 2021. Conference Call and Webcast Details. That is because the Jun 17, 2022 $0.50 Call had some of the highest implied volatility of all equity options today. Press question mark to learn the rest of the keyboard shortcuts MALVERN, PA Ocugen, Inc. (NASDAQ: OCGN) announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8:30 a.m. You may book discounted hotel rooms at the Fontainebleau Hotel via . Ocugen reported a $0.09 net loss per share for the three months ended March 31, 2022 compared to a $0.04 net loss per share for the three months ended March 31, 2021. Ocugene. Trending now. MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its third quarter 2021 financial results and provide a business update at 8 .